WuXi borrows $165m from Asian banks for M&A deals in 2015

By Zachary Brennan contact

- Last updated on GMT

Related tags: Cro wuxi pharmatech, Credit, Finance, Jiangsu

The new credit will allow the company to seek out new acquisitions without stopping its capacity expansion plans
The new credit will allow the company to seek out new acquisitions without stopping its capacity expansion plans
China-based CRO WuXi PharmaTech has entered into a syndicated loan facility to borrow up to $165m from a consortium of banks in Asia to seek out new acquisitions. 

WuXi capital spending is expected to double over the next year as it was approximately $110m in 2014 and will be about $200m in 2015. Recent acquisitions seem to indicate the company is moving away from its core of contract service offerings as they include the purchase of XenoBiotic Laboratories for $37.5m ​and NextCODE Health for $65m​.

"This new loan agreement provides WuXi with the resources to invest in several new business opportunities without impacting the strong growth of our current operations​," said Edward Hu, CFO of WuXi.

He also explained that in order to meet the growing demand, the company is building $150m small-molecule manufacturing facilities in Changzhou, China, that will double current capacity by late 2015 or early 2016; biologics commercial manufacturing facilities in Wuxi city that will also cost nearly $150m and be completed by late 2016; and two cell-therapy manufacturing facilities in Philadelphia that will cost about $40m.

Dr. Ge Li, Chairman and CEO of WuXi PharmaTech, added: "While continuously strengthening our existing capabilities, we also see new investment opportunities in the rapidly growing China healthcare market. We need to invest aggressively to extend our research and development capabilities to hospitals, doctors, and patients to capture many of these exciting opportunities​."

The company did not respond to a request for comment on what types of companies it was targeting with these new funds.

The borrowing will incur interest at a rate of LIBOR plus 2.89%, including all expenses, and will be repaid in four installments over 18-36 months, WuXi added.

Related news

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars